No Benefit To Increasing Dose Intensity Of Chemotherapy In Osteosarcoma, Study Finds

... A dose-intensive regimen of the chemotherapy drugs cisplatin and doxorubicin offered no clinical benefit over standard doses of the chemotherapy drugs in patients with a bone cancer called osteosarcoma, according to results from a randomized trial in the Jan. 17 issue of the Journal of the National Cancer Institute. Although the dose-intensive regimen killed tumor cells better than the standard regimen after surgery, survival rates were similar in both groups. ...